nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—SULT1E1—gonad—testicular cancer	0.0228	0.292	CbGeAlD
Cyclizine—Dyskinesia—Chlorambucil—testicular cancer	0.0203	0.022	CcSEcCtD
Cyclizine—Muscle twitching—Chlorambucil—testicular cancer	0.0194	0.0211	CcSEcCtD
Cyclizine—SULT1E1—female gonad—testicular cancer	0.0185	0.237	CbGeAlD
Cyclizine—SULT1E1—testis—testicular cancer	0.0164	0.21	CbGeAlD
Cyclizine—Dyskinesia—Ifosfamide—testicular cancer	0.0134	0.0146	CcSEcCtD
Cyclizine—Muscle twitching—Ifosfamide—testicular cancer	0.0128	0.0139	CcSEcCtD
Cyclizine—Depressed level of consciousness—Ifosfamide—testicular cancer	0.0122	0.0132	CcSEcCtD
Cyclizine—Disorientation—Bleomycin—testicular cancer	0.012	0.013	CcSEcCtD
Cyclizine—SULT1E1—lymph node—testicular cancer	0.0119	0.153	CbGeAlD
Cyclizine—Apnoea—Etoposide—testicular cancer	0.0117	0.0127	CcSEcCtD
Cyclizine—Pain—Carboplatin—testicular cancer	0.0113	0.0123	CcSEcCtD
Cyclizine—Thrombophlebitis—Ifosfamide—testicular cancer	0.0106	0.0115	CcSEcCtD
Cyclizine—Hepatic function abnormal—Ifosfamide—testicular cancer	0.0105	0.0114	CcSEcCtD
Cyclizine—Disorientation—Ifosfamide—testicular cancer	0.0102	0.0111	CcSEcCtD
Cyclizine—Agranulocytosis—Vinblastine—testicular cancer	0.00912	0.00989	CcSEcCtD
Cyclizine—Bronchospasm—Bleomycin—testicular cancer	0.00911	0.00988	CcSEcCtD
Cyclizine—Urinary retention—Ifosfamide—testicular cancer	0.0087	0.00944	CcSEcCtD
Cyclizine—Tremor—Chlorambucil—testicular cancer	0.00781	0.00847	CcSEcCtD
Cyclizine—Bronchospasm—Ifosfamide—testicular cancer	0.00778	0.00844	CcSEcCtD
Cyclizine—Blister—Epirubicin—testicular cancer	0.00775	0.0084	CcSEcCtD
Cyclizine—Agitation—Chlorambucil—testicular cancer	0.00766	0.00831	CcSEcCtD
Cyclizine—Angioedema—Chlorambucil—testicular cancer	0.00762	0.00826	CcSEcCtD
Cyclizine—Convulsion—Chlorambucil—testicular cancer	0.00722	0.00783	CcSEcCtD
Cyclizine—Agranulocytosis—Dactinomycin—testicular cancer	0.00718	0.00779	CcSEcCtD
Cyclizine—Blister—Doxorubicin—testicular cancer	0.00717	0.00777	CcSEcCtD
Cyclizine—Apnoea—Methotrexate—testicular cancer	0.00704	0.00763	CcSEcCtD
Cyclizine—Speech disorder—Methotrexate—testicular cancer	0.00694	0.00752	CcSEcCtD
Cyclizine—Hepatitis—Dactinomycin—testicular cancer	0.00691	0.0075	CcSEcCtD
Cyclizine—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00667	0.00724	CcSEcCtD
Cyclizine—Chills—Bleomycin—testicular cancer	0.00665	0.00721	CcSEcCtD
Cyclizine—Convulsion—Vinblastine—testicular cancer	0.00662	0.00718	CcSEcCtD
Cyclizine—Hypertension—Vinblastine—testicular cancer	0.00659	0.00715	CcSEcCtD
Cyclizine—Agranulocytosis—Ifosfamide—testicular cancer	0.00658	0.00714	CcSEcCtD
Cyclizine—Erythema—Bleomycin—testicular cancer	0.00645	0.007	CcSEcCtD
Cyclizine—Jaundice cholestatic—Epirubicin—testicular cancer	0.00635	0.00689	CcSEcCtD
Cyclizine—Hepatitis—Ifosfamide—testicular cancer	0.00633	0.00687	CcSEcCtD
Cyclizine—Connective tissue disorder—Ifosfamide—testicular cancer	0.00622	0.00675	CcSEcCtD
Cyclizine—Chills—Dactinomycin—testicular cancer	0.0062	0.00673	CcSEcCtD
Cyclizine—Bronchospasm—Etoposide—testicular cancer	0.00615	0.00667	CcSEcCtD
Cyclizine—Erythema—Dactinomycin—testicular cancer	0.00602	0.00653	CcSEcCtD
Cyclizine—Dyskinesia—Epirubicin—testicular cancer	0.00594	0.00644	CcSEcCtD
Cyclizine—Eye disorder—Ifosfamide—testicular cancer	0.00592	0.00642	CcSEcCtD
Cyclizine—Jaundice cholestatic—Doxorubicin—testicular cancer	0.00588	0.00638	CcSEcCtD
Cyclizine—Pain—Chlorambucil—testicular cancer	0.00582	0.00631	CcSEcCtD
Cyclizine—Depressed level of consciousness—Methotrexate—testicular cancer	0.00576	0.00625	CcSEcCtD
Cyclizine—Hepatobiliary disease—Cisplatin—testicular cancer	0.00575	0.00624	CcSEcCtD
Cyclizine—Chills—Ifosfamide—testicular cancer	0.00568	0.00616	CcSEcCtD
Cyclizine—Paraesthesia—Vinblastine—testicular cancer	0.0056	0.00607	CcSEcCtD
Cyclizine—Injection site reaction—Epirubicin—testicular cancer	0.00555	0.00602	CcSEcCtD
Cyclizine—Mental disorder—Ifosfamide—testicular cancer	0.00555	0.00602	CcSEcCtD
Cyclizine—Erythema—Ifosfamide—testicular cancer	0.00551	0.00598	CcSEcCtD
Cyclizine—Dyskinesia—Doxorubicin—testicular cancer	0.0055	0.00596	CcSEcCtD
Cyclizine—Urticaria—Chlorambucil—testicular cancer	0.0054	0.00586	CcSEcCtD
Cyclizine—Connective tissue disorder—Cisplatin—testicular cancer	0.00537	0.00582	CcSEcCtD
Cyclizine—Constipation—Vinblastine—testicular cancer	0.00533	0.00578	CcSEcCtD
Cyclizine—Pain—Vinblastine—testicular cancer	0.00533	0.00578	CcSEcCtD
Cyclizine—Hepatobiliary disease—Etoposide—testicular cancer	0.00527	0.00572	CcSEcCtD
Cyclizine—Anaphylactic shock—Bleomycin—testicular cancer	0.00526	0.00571	CcSEcCtD
Cyclizine—Agranulocytosis—Etoposide—testicular cancer	0.0052	0.00564	CcSEcCtD
Cyclizine—Vision blurred—Ifosfamide—testicular cancer	0.0052	0.00564	CcSEcCtD
Cyclizine—Injection site reaction—Doxorubicin—testicular cancer	0.00514	0.00557	CcSEcCtD
Cyclizine—Eye disorder—Cisplatin—testicular cancer	0.0051	0.00553	CcSEcCtD
Cyclizine—Agitation—Ifosfamide—testicular cancer	0.00507	0.0055	CcSEcCtD
Cyclizine—Angioedema—Ifosfamide—testicular cancer	0.00504	0.00546	CcSEcCtD
Cyclizine—Hypersensitivity—Chlorambucil—testicular cancer	0.00501	0.00544	CcSEcCtD
Cyclizine—Thrombophlebitis—Methotrexate—testicular cancer	0.005	0.00543	CcSEcCtD
Cyclizine—Hypotension—Bleomycin—testicular cancer	0.00492	0.00534	CcSEcCtD
Cyclizine—Asthenia—Chlorambucil—testicular cancer	0.00488	0.00529	CcSEcCtD
Cyclizine—Pruritus—Chlorambucil—testicular cancer	0.00481	0.00522	CcSEcCtD
Cyclizine—Convulsion—Ifosfamide—testicular cancer	0.00478	0.00518	CcSEcCtD
Cyclizine—Hypertension—Ifosfamide—testicular cancer	0.00476	0.00516	CcSEcCtD
Cyclizine—Erythema—Cisplatin—testicular cancer	0.00475	0.00516	CcSEcCtD
Cyclizine—Paraesthesia—Bleomycin—testicular cancer	0.00473	0.00513	CcSEcCtD
Cyclizine—Thrombophlebitis—Epirubicin—testicular cancer	0.00468	0.00508	CcSEcCtD
Cyclizine—Eye disorder—Etoposide—testicular cancer	0.00467	0.00507	CcSEcCtD
Cyclizine—Hepatic function abnormal—Epirubicin—testicular cancer	0.00464	0.00503	CcSEcCtD
Cyclizine—Hypersensitivity—Vinblastine—testicular cancer	0.00459	0.00498	CcSEcCtD
Cyclizine—Muscle spasms—Cisplatin—testicular cancer	0.00457	0.00496	CcSEcCtD
Cyclizine—Pain—Bleomycin—testicular cancer	0.0045	0.00488	CcSEcCtD
Cyclizine—Anaphylactic shock—Ifosfamide—testicular cancer	0.0045	0.00488	CcSEcCtD
Cyclizine—Chills—Etoposide—testicular cancer	0.00449	0.00487	CcSEcCtD
Cyclizine—Vision blurred—Cisplatin—testicular cancer	0.00448	0.00486	CcSEcCtD
Cyclizine—Asthenia—Vinblastine—testicular cancer	0.00447	0.00485	CcSEcCtD
Cyclizine—Tremor—Cisplatin—testicular cancer	0.00445	0.00483	CcSEcCtD
Cyclizine—Nervous system disorder—Ifosfamide—testicular cancer	0.00441	0.00479	CcSEcCtD
Cyclizine—Skin disorder—Ifosfamide—testicular cancer	0.00437	0.00474	CcSEcCtD
Cyclizine—Thrombophlebitis—Doxorubicin—testicular cancer	0.00433	0.0047	CcSEcCtD
Cyclizine—Hepatic function abnormal—Doxorubicin—testicular cancer	0.00429	0.00465	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—testicular cancer	0.00424	0.0046	CcSEcCtD
Cyclizine—Hypotension—Ifosfamide—testicular cancer	0.0042	0.00456	CcSEcCtD
Cyclizine—Pain—Dactinomycin—testicular cancer	0.0042	0.00455	CcSEcCtD
Cyclizine—Muscle spasms—Etoposide—testicular cancer	0.00419	0.00454	CcSEcCtD
Cyclizine—Urticaria—Bleomycin—testicular cancer	0.00418	0.00454	CcSEcCtD
Cyclizine—Dizziness—Vinblastine—testicular cancer	0.00412	0.00447	CcSEcCtD
Cyclizine—Convulsion—Cisplatin—testicular cancer	0.00412	0.00447	CcSEcCtD
Cyclizine—Paraesthesia—Ifosfamide—testicular cancer	0.00404	0.00438	CcSEcCtD
Cyclizine—Somnolence—Ifosfamide—testicular cancer	0.004	0.00434	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—testicular cancer	0.00392	0.00426	CcSEcCtD
Cyclizine—Headache—Vinblastine—testicular cancer	0.0039	0.00424	CcSEcCtD
Cyclizine—Anaphylactic shock—Cisplatin—testicular cancer	0.00388	0.00421	CcSEcCtD
Cyclizine—Hypersensitivity—Bleomycin—testicular cancer	0.00388	0.00421	CcSEcCtD
Cyclizine—Pain—Ifosfamide—testicular cancer	0.00385	0.00417	CcSEcCtD
Cyclizine—Constipation—Ifosfamide—testicular cancer	0.00385	0.00417	CcSEcCtD
Cyclizine—Nervous system disorder—Cisplatin—testicular cancer	0.0038	0.00413	CcSEcCtD
Cyclizine—Tachycardia—Cisplatin—testicular cancer	0.00379	0.00411	CcSEcCtD
Cyclizine—Asthenia—Bleomycin—testicular cancer	0.00378	0.0041	CcSEcCtD
Cyclizine—Convulsion—Etoposide—testicular cancer	0.00377	0.00409	CcSEcCtD
Cyclizine—Skin disorder—Cisplatin—testicular cancer	0.00377	0.00409	CcSEcCtD
Cyclizine—Hypertension—Etoposide—testicular cancer	0.00376	0.00408	CcSEcCtD
Cyclizine—Pruritus—Bleomycin—testicular cancer	0.00372	0.00404	CcSEcCtD
Cyclizine—Hypotension—Cisplatin—testicular cancer	0.00362	0.00393	CcSEcCtD
Cyclizine—Hypersensitivity—Dactinomycin—testicular cancer	0.00362	0.00392	CcSEcCtD
Cyclizine—Urticaria—Ifosfamide—testicular cancer	0.00357	0.00388	CcSEcCtD
Cyclizine—Anaphylactic shock—Etoposide—testicular cancer	0.00355	0.00385	CcSEcCtD
Cyclizine—Asthenia—Dactinomycin—testicular cancer	0.00352	0.00382	CcSEcCtD
Cyclizine—Paraesthesia—Cisplatin—testicular cancer	0.00348	0.00378	CcSEcCtD
Cyclizine—Tachycardia—Etoposide—testicular cancer	0.00347	0.00376	CcSEcCtD
Cyclizine—Skin disorder—Etoposide—testicular cancer	0.00345	0.00374	CcSEcCtD
Cyclizine—Drowsiness—Methotrexate—testicular cancer	0.00334	0.00362	CcSEcCtD
Cyclizine—Hypotension—Etoposide—testicular cancer	0.00332	0.0036	CcSEcCtD
Cyclizine—Pain—Cisplatin—testicular cancer	0.00332	0.0036	CcSEcCtD
Cyclizine—Hypersensitivity—Ifosfamide—testicular cancer	0.00331	0.0036	CcSEcCtD
Cyclizine—HRH1—female gonad—testicular cancer	0.00331	0.0424	CbGeAlD
Cyclizine—Asthenia—Ifosfamide—testicular cancer	0.00323	0.0035	CcSEcCtD
Cyclizine—Paraesthesia—Etoposide—testicular cancer	0.00319	0.00346	CcSEcCtD
Cyclizine—Pruritus—Ifosfamide—testicular cancer	0.00318	0.00345	CcSEcCtD
Cyclizine—Somnolence—Etoposide—testicular cancer	0.00316	0.00343	CcSEcCtD
Cyclizine—Hepatobiliary disease—Methotrexate—testicular cancer	0.00316	0.00342	CcSEcCtD
Cyclizine—Drowsiness—Epirubicin—testicular cancer	0.00312	0.00339	CcSEcCtD
Cyclizine—Agranulocytosis—Methotrexate—testicular cancer	0.00311	0.00338	CcSEcCtD
Cyclizine—Pain—Etoposide—testicular cancer	0.00304	0.0033	CcSEcCtD
Cyclizine—Constipation—Etoposide—testicular cancer	0.00304	0.0033	CcSEcCtD
Cyclizine—Hepatitis—Methotrexate—testicular cancer	0.003	0.00325	CcSEcCtD
Cyclizine—Dizziness—Ifosfamide—testicular cancer	0.00298	0.00323	CcSEcCtD
Cyclizine—Hepatobiliary disease—Epirubicin—testicular cancer	0.00295	0.0032	CcSEcCtD
Cyclizine—HRH1—testis—testicular cancer	0.00294	0.0376	CbGeAlD
Cyclizine—Agranulocytosis—Epirubicin—testicular cancer	0.00291	0.00316	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—testicular cancer	0.00289	0.00313	CcSEcCtD
Cyclizine—Hypersensitivity—Cisplatin—testicular cancer	0.00286	0.0031	CcSEcCtD
Cyclizine—Urticaria—Etoposide—testicular cancer	0.00282	0.00306	CcSEcCtD
Cyclizine—Hepatitis—Epirubicin—testicular cancer	0.0028	0.00304	CcSEcCtD
Cyclizine—Eye disorder—Methotrexate—testicular cancer	0.0028	0.00304	CcSEcCtD
Cyclizine—Asthenia—Cisplatin—testicular cancer	0.00278	0.00302	CcSEcCtD
Cyclizine—Connective tissue disorder—Epirubicin—testicular cancer	0.00276	0.00299	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00273	0.00296	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—testicular cancer	0.0027	0.00293	CcSEcCtD
Cyclizine—Chills—Methotrexate—testicular cancer	0.00269	0.00292	CcSEcCtD
Cyclizine—Mental disorder—Methotrexate—testicular cancer	0.00262	0.00285	CcSEcCtD
Cyclizine—Eye disorder—Epirubicin—testicular cancer	0.00262	0.00284	CcSEcCtD
Cyclizine—Hypersensitivity—Etoposide—testicular cancer	0.00262	0.00284	CcSEcCtD
Cyclizine—Erythema—Methotrexate—testicular cancer	0.00261	0.00283	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—testicular cancer	0.00259	0.00281	CcSEcCtD
Cyclizine—Asthenia—Etoposide—testicular cancer	0.00255	0.00277	CcSEcCtD
Cyclizine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00255	0.00277	CcSEcCtD
Cyclizine—Chills—Epirubicin—testicular cancer	0.00252	0.00273	CcSEcCtD
Cyclizine—Pruritus—Etoposide—testicular cancer	0.00251	0.00273	CcSEcCtD
Cyclizine—Vision blurred—Methotrexate—testicular cancer	0.00246	0.00267	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—testicular cancer	0.00246	0.00266	CcSEcCtD
Cyclizine—Erythema—Epirubicin—testicular cancer	0.00244	0.00265	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—testicular cancer	0.00242	0.00263	CcSEcCtD
Cyclizine—Tension—Epirubicin—testicular cancer	0.0024	0.0026	CcSEcCtD
Cyclizine—Nervousness—Epirubicin—testicular cancer	0.00237	0.00257	CcSEcCtD
Cyclizine—Dizziness—Etoposide—testicular cancer	0.00235	0.00255	CcSEcCtD
Cyclizine—Muscle spasms—Epirubicin—testicular cancer	0.00235	0.00255	CcSEcCtD
Cyclizine—Chills—Doxorubicin—testicular cancer	0.00233	0.00252	CcSEcCtD
Cyclizine—Vision blurred—Epirubicin—testicular cancer	0.0023	0.00249	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—testicular cancer	0.00227	0.00247	CcSEcCtD
Cyclizine—Convulsion—Methotrexate—testicular cancer	0.00226	0.00245	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—testicular cancer	0.00226	0.00245	CcSEcCtD
Cyclizine—Agitation—Epirubicin—testicular cancer	0.00224	0.00243	CcSEcCtD
Cyclizine—Headache—Etoposide—testicular cancer	0.00223	0.00241	CcSEcCtD
Cyclizine—Tension—Doxorubicin—testicular cancer	0.00222	0.0024	CcSEcCtD
Cyclizine—Nervousness—Doxorubicin—testicular cancer	0.00219	0.00238	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—testicular cancer	0.00217	0.00235	CcSEcCtD
Cyclizine—HRH1—lymph node—testicular cancer	0.00213	0.0273	CbGeAlD
Cyclizine—Anaphylactic shock—Methotrexate—testicular cancer	0.00213	0.00231	CcSEcCtD
Cyclizine—Vision blurred—Doxorubicin—testicular cancer	0.00213	0.00231	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—testicular cancer	0.00211	0.00229	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—testicular cancer	0.00211	0.00229	CcSEcCtD
Cyclizine—Nervous system disorder—Methotrexate—testicular cancer	0.00209	0.00226	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—testicular cancer	0.00208	0.00225	CcSEcCtD
Cyclizine—Skin disorder—Methotrexate—testicular cancer	0.00207	0.00224	CcSEcCtD
Cyclizine—Anaphylactic shock—Epirubicin—testicular cancer	0.00199	0.00216	CcSEcCtD
Cyclizine—Hypotension—Methotrexate—testicular cancer	0.00199	0.00216	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—testicular cancer	0.00196	0.00212	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—testicular cancer	0.00195	0.00212	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—testicular cancer	0.00195	0.00211	CcSEcCtD
Cyclizine—Tachycardia—Epirubicin—testicular cancer	0.00194	0.00211	CcSEcCtD
Cyclizine—Skin disorder—Epirubicin—testicular cancer	0.00193	0.0021	CcSEcCtD
Cyclizine—Insomnia—Methotrexate—testicular cancer	0.00193	0.00209	CcSEcCtD
Cyclizine—Paraesthesia—Methotrexate—testicular cancer	0.00191	0.00207	CcSEcCtD
Cyclizine—Somnolence—Methotrexate—testicular cancer	0.00189	0.00205	CcSEcCtD
Cyclizine—Hypotension—Epirubicin—testicular cancer	0.00186	0.00202	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00184	0.002	CcSEcCtD
Cyclizine—Pain—Methotrexate—testicular cancer	0.00182	0.00197	CcSEcCtD
Cyclizine—Nervous system disorder—Doxorubicin—testicular cancer	0.00181	0.00196	CcSEcCtD
Cyclizine—Insomnia—Epirubicin—testicular cancer	0.0018	0.00195	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—testicular cancer	0.0018	0.00195	CcSEcCtD
Cyclizine—Skin disorder—Doxorubicin—testicular cancer	0.00179	0.00194	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—testicular cancer	0.00179	0.00194	CcSEcCtD
Cyclizine—Somnolence—Epirubicin—testicular cancer	0.00177	0.00192	CcSEcCtD
Cyclizine—Hypotension—Doxorubicin—testicular cancer	0.00172	0.00187	CcSEcCtD
Cyclizine—Pain—Epirubicin—testicular cancer	0.0017	0.00185	CcSEcCtD
Cyclizine—Constipation—Epirubicin—testicular cancer	0.0017	0.00185	CcSEcCtD
Cyclizine—Urticaria—Methotrexate—testicular cancer	0.00169	0.00183	CcSEcCtD
Cyclizine—Insomnia—Doxorubicin—testicular cancer	0.00167	0.00181	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—testicular cancer	0.00166	0.0018	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—testicular cancer	0.00164	0.00178	CcSEcCtD
Cyclizine—Urticaria—Epirubicin—testicular cancer	0.00158	0.00172	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—testicular cancer	0.00158	0.00171	CcSEcCtD
Cyclizine—Pain—Doxorubicin—testicular cancer	0.00158	0.00171	CcSEcCtD
Cyclizine—Hypersensitivity—Methotrexate—testicular cancer	0.00157	0.0017	CcSEcCtD
Cyclizine—Asthenia—Methotrexate—testicular cancer	0.00153	0.00166	CcSEcCtD
Cyclizine—Pruritus—Methotrexate—testicular cancer	0.00151	0.00163	CcSEcCtD
Cyclizine—Hypersensitivity—Epirubicin—testicular cancer	0.00147	0.00159	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—testicular cancer	0.00146	0.00159	CcSEcCtD
Cyclizine—Asthenia—Epirubicin—testicular cancer	0.00143	0.00155	CcSEcCtD
Cyclizine—Pruritus—Epirubicin—testicular cancer	0.00141	0.00153	CcSEcCtD
Cyclizine—Dizziness—Methotrexate—testicular cancer	0.00141	0.00153	CcSEcCtD
Cyclizine—Hypersensitivity—Doxorubicin—testicular cancer	0.00136	0.00147	CcSEcCtD
Cyclizine—Headache—Methotrexate—testicular cancer	0.00133	0.00145	CcSEcCtD
Cyclizine—Asthenia—Doxorubicin—testicular cancer	0.00132	0.00143	CcSEcCtD
Cyclizine—Dizziness—Epirubicin—testicular cancer	0.00132	0.00143	CcSEcCtD
Cyclizine—Pruritus—Doxorubicin—testicular cancer	0.0013	0.00141	CcSEcCtD
Cyclizine—Headache—Epirubicin—testicular cancer	0.00125	0.00135	CcSEcCtD
Cyclizine—Dizziness—Doxorubicin—testicular cancer	0.00122	0.00132	CcSEcCtD
Cyclizine—Headache—Doxorubicin—testicular cancer	0.00115	0.00125	CcSEcCtD
